Skip to main content
Article thumbnail
Location of Repository

90 Yttrium-hydroxyapatite: a new therapeutic option for radioactive synovectomy in haemophilic synovitis

By S. Thomas, M. C. Gabriel, S. A. L. de Souza, S. C . Gomes, P. E. Assi, M. L. Pinheiro Perri, W. Liberato, C . S . Matuchita, B. Gutfilen and L. M. B. da Fonseca


Recurrent haemarthroses often lead to chronic synovitis in patients with haemophilia and von Willebrand disease. Radioactive synovectomy with yttrium-90 ( 90 Y) citrate is frequently used to treat this complication, usually with good results. Since 2006, the Nuclear Energy Research Institute (IPEN, Sao Paulo, Brazil) has produced hydroxyapatite particles labelled with 90 Y for radioactive synovectomy. The aim of this study was to compare the results achieved by both forms of 90 Y in the treatment of haemophilic synovitis. We included 221 joints from 136 patients (age range: 6–20 years), treated by one of the two radiopharmaceu-ticals, at the Hemocenter of Mato Grosso, Brazil. The outcomes analysed were the annual frequency of haem-arthrosis, articular pain and joint range of motion before and 1 year after RS. Similar results were achieved regardless of whether 90 Y hydroxyapatite or 90 Y citrate was used, and results were independent of the joint type, age, gender, radiologic stage and presence of inhibitors. 90 Y hydroxyapatite appears to be equivalent to the reference product 90 Y citrate in the treatment of chronic synovitis associated with bleeding disorders

Topics: Haemophilia, Radioactive Synovectomy, Radiosynovectomy, Synovitis, Yttrium Citrate, Yttrium Hydroxyapatite, Hemofilia A, Sinovite, Ítrio
Publisher: Wiley
Year: 2011
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.